Methods for reducing the recurrence of cardiac arrhythmia
Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.
1. A method for reducing the recurrence of cardiac arrhythmia in a mammal that has previously exhibited cardiac arrhythmia comprising administering to said mammal an effective amount of a compound selected from the group consisting of vanoxerine, 1-[(2-(bis-(4-fluorophenyl)methoxy)ethyl]-4-(3-phenylpropenyl)-piperazine, 1-[(2-diphenyl-methoxy)ethyl]-4-(3-phenylpropenyl)-piperazine, and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein a pharmaceutically acceptable salt of vanoxerine is administered.
3. The method of claim 1 , wherein said pharmaceutically acceptable salt is selected from the group consisting of salts derived from hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succine acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicyclic acid, sulfanilic acid, 2-acetoxy-benzoic acid, fumaric acid, toluenesulfonic acid, methansulfonic acid, ethane disulfonic acid, oxalic acid, isethionic acid, trifluoroacetic acid, glutamic acid and aspartic acid.
4. The method of claim 1 , wherein the mammal is a human.
5. The method of claim 1 , wherein said vanoxerine or said pharmaceutically acceptable salt, thereof is administered in combination with a pharmaceutically acceptable carrier or vehicle.